Skip to main content
Top
Published in: Medical Microbiology and Immunology 5/2020

01-10-2020 | Amphotericin B | Original Investigation

Luliconazole, a highly effective imidazole, against Fusarium species complexes

Authors: Maral Gharaghani, Sahar Hivary, Simin Taghipour, Ali Zarei-Mahmoudabadi

Published in: Medical Microbiology and Immunology | Issue 5/2020

Login to get access

Abstract

Luliconazole is a new antifungal that was primarily used for the treatment of dermatophytosis. However, some studies have shown that it has excellent efficacy against Aspergillus and Candida species in vitro. The present study aimed to evaluate of luliconazole activity against some Fusarium species complex isolates. In this study, 47 isolates of Fusarium were tested against several antifungals including luliconazole. All species were identified using morphology features, and PCR sequencing and antifungal susceptibility were performed according to CLSIM38 A3 guideline. Our results revealed that luliconazole has a very low minimum inhibitory concentration value (0.0078–1 µg/ml) in comparison with other tested antifungals. Amphotericin B had a poor effect with a high MIC90 (64 µg/ml), followed by terbinafine (32 µg/ml), posaconazole (16 µg/ml), caspofungin (16 µg/ml), voriconazole (4 µg/ml), and itraconazole (4 µg/ml). Overall, our findings indicated that luliconazole has great activity against environmental and clinical Fusarium species complexes in comparison to tested antifungals.
Literature
2.
go back to reference Jarratt M, Jones T, Adelglass J et al (2014) Efficacy and safety of once-daily luliconazole 1% cream in patients ≥ 12 years of age with interdigital tinea pedis: a phase 3, randomized, double-blind, vehicle-controlled study. J Drugs Dermatol 13(7):838–846PubMed Jarratt M, Jones T, Adelglass J et al (2014) Efficacy and safety of once-daily luliconazole 1% cream in patients ≥ 12 years of age with interdigital tinea pedis: a phase 3, randomized, double-blind, vehicle-controlled study. J Drugs Dermatol 13(7):838–846PubMed
32.
go back to reference CLSI (2017) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 3rd ed. CLSI document M38-3rd. Clinical and Laboratory Standards Institute, Wayne, PA CLSI (2017) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 3rd ed. CLSI document M38-3rd. Clinical and Laboratory Standards Institute, Wayne, PA
34.
go back to reference Draelos ZD, Vlahovic TC, Gold MH, Parish LC, Korotzer A (2014) A randomized, double-blind, vehicle-controlled trial of luliconazole cream 1% in the treatment of interdigital tinea pedis. J Clin Aesthet Dermatol 7(10):20–27PubMedPubMedCentral Draelos ZD, Vlahovic TC, Gold MH, Parish LC, Korotzer A (2014) A randomized, double-blind, vehicle-controlled trial of luliconazole cream 1% in the treatment of interdigital tinea pedis. J Clin Aesthet Dermatol 7(10):20–27PubMedPubMedCentral
Metadata
Title
Luliconazole, a highly effective imidazole, against Fusarium species complexes
Authors
Maral Gharaghani
Sahar Hivary
Simin Taghipour
Ali Zarei-Mahmoudabadi
Publication date
01-10-2020
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 5/2020
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-020-00672-4

Other articles of this Issue 5/2020

Medical Microbiology and Immunology 5/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.